Letters21 September 2010
    Author, Article and Disclosure Information

    TO THE EDITOR:

    Parker and colleagues (1) found no significant association between fetuin-A levels and mortality in a cohort with prevalent coronary artery disease. Our understanding of fetuin-A biology is greatly undermined by the lack of agreement among different methods of measurement. It is therefore particularly important that method descriptions are unambiguous. The authors comment that their nephelometric fetuin-A assay “uses the same high-specificity antibody as commercially available enzyme-linked immunosorbent assays.” It is unclear to which commercially available assays they are referring—the 2 most widely used commercial kits not only use different antisera but also use a sandwich format with ...

    References

    • 1. Parker BD Schurgers LJ Brandenburg VM Christenson RH Vermeer C Ketteler M et alThe associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med2010;152:640-8. [PMID: 20479029] LinkGoogle Scholar
    • 2. Smith ER Ford ML Tomlinson LA Rocks BF Rajkumar C Holt SG Poor agreement between commercial ELISAs for plasma fetuin-A: an effect of protein glycosylation? Clin Chim Acta2010;411:1367-70. [PMID: 20420817] CrossrefMedlineGoogle Scholar
    • 3. Hermans MM Brandenburg V Ketteler M Kooman JP van der Sande FM Boeschoten EW et alNetherlands cooperative study on the adequacy of Dialysis (NECOSAD)Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int2007;72:202-7. [PMID: 17342178] CrossrefMedlineGoogle Scholar
    • 4. Ford ML Tomlinson LA Smith ER Rajkumar C Holt SG Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant2010;25:1853-8. [PMID: 20075438] CrossrefMedlineGoogle Scholar